Amid ongoing concerns about the cost and supply of GLP-1s, a new study suggests that a wide swath of American adults would ...

The new class of GLP-1 weight loss drugs have been blockbusters since they arrived on the market a few years ago. These ...

Strata Decision Technology data finds the number of bariatric surgeries in the Chicago area may have fallen by more than half ...

Semaglutide being investigated for applications in heart disease, Alzheimer's, liver disease, and more GLP-1 drugs expected ...

GLP-1 drugs like Ozempic are injectable medications—but a strange new market has emerged selling oral “compounded” versions ...

Now available in the US, AllurionMeds aims to address common concerns around the use and affordability of GLP-1 weight loss ...

Popular weight loss drugs have been linked to gastrointestinal, mental health, and vision problems, but the benefits appear ...

A groundbreaking Harvard study reveals that semaglutide could benefit more people in the U.S. than ever imagined.

Findings suggest semaglutide and other GLP-1 agonists may significantly reduce alcohol use disorder hospitalizations, ...

However, the $730 billion Danish pharmaceutical giant Novo Nordisk quelled fears of a shortfall in supply in semaglutide-based GLP-1 drugs, with the introduction of Wegovy to the Australian market.

Losing face? Take heart. A new supplement promises to put an end to the emaciated aesthetic of ‘Ozempic face.’ ...

Like semaglutide (the active ingredient in Ozempic and Wegovy ... Eli Lilly may beat Viking Therapeutics to get the first ...